CA
NZ
UK
AU
IND
US
● The product is made in South Carolina with Nephron Pharmaceuticals using blow-fill-seal technology.
● Second-quarter totalRevenuewas only $57 million, less than half the milestone.
● Dupixent global net sales reached $6.5 billion, up 35% from a year earlier.
● ResMed returned more than $1.0 billion to shareholders, including $936.4 million in buybacks.
● Adjusted freeCash Flowreportedly fell 38%, the main counterweight.
● The FDA set a Nov. 30, 2026 target action date for accelerated approval.
● Third-quarterRevenuerose 39% to $24.4 billion on Mounjaro and Zepbound demand.
● A brokerage raised its price target to $1,497 from $1,397.
● Third-quarterRevenuewas $15.03 billion, up 4.4% from a year earlier.
● Global Dupixent sales reached $6.5 billion in the quarter, up 35%.
Please wait processing your request...